Capricor Therapeutics, Inc. (CAPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

The Law Offices of Howard G. Smith is soliciting Capricor Therapeutics (CAPR) investors with substantial losses to seek lead-plaintiff status in a pending securities fraud class action, with a deadline of September 28, 2026. The underlying suit alleges that between December 17, 2025 and July 26, 2026, defendants concealed changes to the pre-specified statistical analysis plan for Deramiocel and that the FDA had not agreed to those changes before the BLA resubmission, creating substantial risk to approval for Duchenne muscular dystrophy.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.